259 related articles for article (PubMed ID: 23955641)
1. Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.
Matsuno A; Murakami M; Hoya K; Yamada SM; Miyamoto S; Yamada S; Son JH; Nishido H; Ide F; Nagashima H; Sugaya M; Hirohata T; Mizutani A; Okinaga H; Ishii Y; Tahara S; Teramoto A; Osamura RY
Med Mol Morphol; 2014 Mar; 47(1):1-7. PubMed ID: 23955641
[TBL] [Abstract][Full Text] [Related]
2. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
Hirohata T; Asano K; Ogawa Y; Takano S; Amano K; Isozaki O; Iwai Y; Sakata K; Fukuhara N; Nishioka H; Yamada S; Fujio S; Arita K; Takano K; Tominaga A; Hizuka N; Ikeda H; Osamura RY; Tahara S; Ishii Y; Kawamata T; Shimatsu A; Teramoto A; Matsuno A
J Clin Endocrinol Metab; 2013 Mar; 98(3):1130-6. PubMed ID: 23365123
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
[TBL] [Abstract][Full Text] [Related]
4. The role of temozolomide in the treatment of aggressive pituitary tumors.
Liu JK; Patel J; Eloy JA
J Clin Neurosci; 2015 Jun; 22(6):923-9. PubMed ID: 25772801
[TBL] [Abstract][Full Text] [Related]
5. MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.
Salehi F; Scheithauer BW; Kros JM; Lau Q; Fealey M; Erickson D; Kovacs K; Horvath E; Lloyd RV
J Neurooncol; 2011 Sep; 104(3):647-57. PubMed ID: 21311951
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M
Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588
[TBL] [Abstract][Full Text] [Related]
7. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
[TBL] [Abstract][Full Text] [Related]
8. O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?
Widhalm G; Wolfsberger S; Preusser M; Woehrer A; Kotter MR; Czech T; Marosi C; Knosp E
Cancer; 2009 Mar; 115(5):1070-80. PubMed ID: 19156926
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide in aggressive pituitary adenomas and carcinomas.
Ortiz LD; Syro LV; Scheithauer BW; Rotondo F; Uribe H; Fadul CE; Horvath E; Kovacs K
Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):119-23. PubMed ID: 22584716
[TBL] [Abstract][Full Text] [Related]
10. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
McCormack AI; Wass JA; Grossman AB
Eur J Clin Invest; 2011 Oct; 41(10):1133-48. PubMed ID: 21496012
[TBL] [Abstract][Full Text] [Related]
11. Treatment of pituitary neoplasms with temozolomide: a review.
Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E
Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485
[TBL] [Abstract][Full Text] [Related]
12. MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.
Micko ASG; Wöhrer A; Höftberger R; Vila G; Marosi C; Knosp E; Wolfsberger S
Pituitary; 2017 Dec; 20(6):643-653. PubMed ID: 28900805
[TBL] [Abstract][Full Text] [Related]
13. How effective is temozolomide for treating pituitary tumours and when should it be used?
Halevy C; Whitelaw BC
Pituitary; 2017 Apr; 20(2):261-266. PubMed ID: 27581836
[TBL] [Abstract][Full Text] [Related]
14. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
Zhao Y; Xiao Z; Chen W; Yang J; Li T; Fan B
Mol Med Rep; 2015 Aug; 12(2):2313-22. PubMed ID: 25937029
[TBL] [Abstract][Full Text] [Related]
15. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
Losa M; Mazza E; Terreni MR; McCormack A; Gill AJ; Motta M; Cangi MG; Talarico A; Mortini P; Reni M
Eur J Endocrinol; 2010 Dec; 163(6):843-51. PubMed ID: 20870708
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review.
Curtò L; Torre ML; Ferraù F; Pitini V; Altavilla G; Granata F; Longo M; Hofland LJ; Trimarchi F; Cannavò S
ScientificWorldJournal; 2010 Nov; 10():2132-8. PubMed ID: 21057727
[TBL] [Abstract][Full Text] [Related]
18. MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern.
Zuhur SS; Tanik C; Karaman Ö; Velet S; Çil E; Öztürk FY; Özkayalar H; Müslüman AM; Altuntaş Y
Endocrine; 2011 Oct; 40(2):222-7. PubMed ID: 21792693
[TBL] [Abstract][Full Text] [Related]
19. MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.
Fealey ME; Scheithauer BW; Horvath E; Erickson D; Kovacs K; McLendon R; Lloyd RV
Endocr Pathol; 2010 Sep; 21(3):161-5. PubMed ID: 20480258
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M
Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
